Choi MK - Search Results

1

Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract.

Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park SH, Park JO, Kim WS, Kang WK, Lee HM, Choi HY, Lim H. Hong JY, et al. Among authors: choi mk, choi hy. Med Oncol. 2009;26(2):186-92. doi: 10.1007/s12032-008-9106-7. Epub 2008 Nov 6. Med Oncol. 2009. PMID: 18988001

2

The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma.

Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ. Hong JY, et al. Among authors: choi mk. Med Oncol. 2009;26(3):287-91. doi: 10.1007/s12032-008-9117-4. Epub 2008 Nov 7. Med Oncol. 2009. PMID: 18989796

3

Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment.

Park MJ, Lee J, Hong JY, Choi MK, Yi JH, Lee SJ, Oh SJ, Ahn JS, Park K, Ahn MJ. Park MJ, et al. Among authors: choi mk. Cancer. 2009 Apr 1;115(7):1518-30. doi: 10.1002/cncr.24151. Cancer. 2009. PMID: 19177485 Free article.

4

Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA).

Choi MK, Park YH, Hong JY, Park HC, Ahn YC, Kim K, Shim YM, Kang WK, Park K, Im YH. Choi MK, et al. Med Oncol. 2010 Dec;27(4):1234-8. doi: 10.1007/s12032-009-9364-z. Epub 2009 Nov 19. Med Oncol. 2010. PMID: 19924573

5

Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.

Choi MK, Choi JY, Lee J, Heo JS, Choi SH, Choi DW, Lee KT, Lee JK, Lee KH, Park JO, Park YS, Lim HY. Choi MK, et al. Among authors: choi dw, choi sh, choi jy. Med Oncol. 2014 Jul;31(7):23. doi: 10.1007/s12032-014-0023-7. Epub 2014 Jun 10. Med Oncol. 2014. PMID: 24909509 Clinical Trial.

6

Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding.

Choi MK, Ahn BJ, Yim DS, Park YS, Kim S, Sohn TS, Noh JH, Heo JS, Lee J, Park SH, Park JO, Lim HY, Kang WK. Choi MK, et al. Cancer Chemother Pharmacol. 2011 Jan;67(1):5-11. doi: 10.1007/s00280-010-1272-6. Epub 2010 Mar 6. Cancer Chemother Pharmacol. 2011. PMID: 20213078 Clinical Trial.

7

Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.

Ahn BJ, Choi MK, Park YS, Lee J, Park SH, Park JO, Lim HY, Kang WK, Ko JW, Yim DS. Ahn BJ, et al. Among authors: choi mk. Eur J Clin Pharmacol. 2010 Dec;66(12):1235-45. doi: 10.1007/s00228-010-0885-3. Epub 2010 Sep 9. Eur J Clin Pharmacol. 2010. PMID: 20827550

8

Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma.

Chang W, Lee SJ, Park S, Choi MK, Hong JY, Kim YS, Maeng CH, Jung HA, Kim S, Lee J. Chang W, et al. Among authors: choi mk. Melanoma Res. 2013 Apr;23(2):147-51. doi: 10.1097/CMR.0b013e32835efd8d. Melanoma Res. 2013. PMID: 23411477

9

Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.

Maeng CH, Yi JH, Lee J, Hong JY, Choi MK, Jung HA, Park JO, Park SH, Park YS, Kang WK, Lim HY. Maeng CH, et al. Among authors: choi mk. Anticancer Res. 2013 Oct;33(10):4619-26. Anticancer Res. 2013. PMID: 24123039

10

Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?

Lee JY, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ. Lee JY, et al. Among authors: choi mk. Cancer Chemother Pharmacol. 2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25. Cancer Chemother Pharmacol. 2014. PMID: 24663503

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

517 results

Search Page